SG Americas Securities
LAB icon

SG Americas Securities’s Standard BioTools LAB Stock Holding History

SG Americas Securities’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47K Buy
56,585
+35,680
+171% +$33.7K ﹤0.01% 3213
2026
Q1 		$19K Sell
20,905
-73,226
-78% -$88.6K ﹤0.01% 3105
2025
Q4 		$120K Buy
94,131
+61,092
+185% +$82.1K ﹤0.01% 3146
2025
Q3 		$43K Buy
33,039
+20,700
+168% +$27.1K ﹤0.01% 3215
2025
Q2 		$15K Sell
12,339
-84,558
-87% -$93.7K ﹤0.01% 2843
2025
Q1 		$105K Sell
96,897
-39,030
-29% -$54.8K ﹤0.01% 3011
2024
Q4 		$238K Buy
135,927
+34,670
+34% +$64.6K ﹤0.01% 1989
2024
Q3 		$195K Buy
101,257
+52,970
+110% +$104K ﹤0.01% 2519
2024
Q2 		$85K Buy
48,287
+22,193
+85% +$54.2K ﹤0.01% 2584
2024
Q1 		$71K Buy
+26,094
New +$63K ﹤0.01% 2657
2022
Q2 		– Sell
-16,815
Closed -$60K – 3507
2022
Q1 		$60K Sell
16,815
-3,500
-17% -$12.1K ﹤0.01% 2824
2021
Q4 		$80K Sell
20,315
-24,395
-55% -$114K ﹤0.01% 3125
2021
Q3 		$295K Buy
+44,710
New +$294K ﹤0.01% 2956
2021
Q2 		– Sell
-11,572
Closed -$52K – 3060
2021
Q1 		$52K Sell
11,572
-4,441
-28% -$24.4K ﹤0.01% 3156
2020
Q4 		$96K Buy
+16,013
New +$105K ﹤0.01% 3057
2020
Q3 		– Sell
-38,817
Closed -$156K – 3096
2020
Q2 		$156K Buy
38,817
+23,483
+153% +$81.8K ﹤0.01% 3067
2020
Q1 		$39K Buy
15,334
+214
+1% +$703 ﹤0.01% 3215
2019
Q4 		$53K Buy
15,120
+4,751
+46% +$16.7K ﹤0.01% 3058
2019
Q3 		$48K Sell
10,369
-424,663
-98% -$3.34M ﹤0.01% 2819
2019
Q2 		$5.36M Buy
+435,032
New +$5.54M 0.04% 504
2016
Q4 		– Sell
-12,031
Closed -$96K – 3317
2016
Q3 		$96K Buy
+12,031
New +$110K ﹤0.01% 3082
2014
Q4 		– Sell
-4,441
Closed -$109K – 3265
2014
Q3 		$109K Buy
4,441
+673
+18% +$18.9K ﹤0.01% 2336
2014
Q2 		$111K Buy
+3,768
New +$121K ﹤0.01% 2304
2013
Q4 		– Sell
-4,955
Closed -$109K – 2835
2013
Q3 		$109K Buy
+4,955
New +$97.3K ﹤0.01% 2619

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

SG Americas Securities's LAB Position: Q2 2026 in Review

SG Americas Securities increased its Standard BioTools (LAB) stake by 171% in Q2 2026, buying an estimated $33.7K and bringing the position to 56,585 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #3213.

SG Americas Securities first reported a position in LAB in Q3 2013 and has held it in 24 quarters since. The position peaked at $5.36M in Q2 2019. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • SG Americas Securities held 56,585 shares of Standard BioTools worth $47K as of Q2 2026.
  • SG Americas Securities bought 35,680 Standard BioTools shares in Q2 2026, an estimated $33.7K.
  • Standard BioTools made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3213 holding.
  • SG Americas Securities first reported a position in Standard BioTools in Q3 2013 and has held it in 24 quarters since.
  • SG Americas Securities's Standard BioTools position peaked at $5.36M in Q2 2019.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.